Refractory chronic spontaneous urticaria after the use of alemtuzumab in multiple sclerosis

Hannah Hu, MBBS, MMed, Stephen Reddell, MBBS, PhD, Sean Riminton, MBChB, PhD, Charles Chan, MBBS, PhD, and Nicolás Urriola, MBBS

Correspondence

Dr. Hu
hannah.hu@health.nsw.gov.au

Neurol Neuroimmunol Neuroinflamm 2020;7:e661. doi:10.1212/NXI.0000000000000661
e661

A 40-year-old woman developed erythematous, raised and pruritic, migratory lesions on a daily basis affecting her whole body for the past 3 months; the appearance of the rash was consistent with urticaria. There was associated angioedema affecting her lips and face. Her medical history was significant for MS, diagnosed 9 years before, manifesting clinically with mobility, speech, and cognitive impairment. Initial treatment was with β -interferon and glatiramer acetate; however, disease relapse prompted switching to alemtuzumab, with 2 standard courses given 12 months apart (60 and 36 mg, respectively, the last dose given 12 months before the onset of rash), and achieved remission with a new baseline Expanded Disability Status Scale of 2.

Ancillary history includes short-lived, asymptomatic, subclinical hypothyroidism before 13 years for which she was given thyroxine during pregnancy. Months after her first dose of alemtuzumab, she developed mild symptomatic hyperthyroidism with persistent thyroglobulin antibodies. Carbimazole was given for a year but ceased after her thyroid function tests normalized. She remained persistently thyroglobulin antibody seropositive. No other subsequent secondary autoimmune diseases manifested with otherwise normal laboratory results.

At the time of development of urticaria, she was on long-term venlafaxine and dexamphetamine for a mood disorder. There was no history to suggest an allergic reaction to current medications. Differential blood count, C-reactive protein, and erythrocyte sedimentation rate did not suggest any chronic or recurrent infections triggering urticaria. Specific IgE to dust mite, grass pollen mix, and staple food was negative.

A clinical diagnosis of chronic spontaneous urticaria (CSU) was made, and she was treated with a maximal dose of histamine (H1/H2) receptor blockade (cetirizine 20 mg bis die and ranitidine 150 mg bis die). Despite this treatment, she continued to have breakthrough urticaria and required intermittent high dose prednisolone (1 mg/kg/d) while still scoring 42 on the Urticaria Activity Score over 7 Days scale. Therapy was intensified with omalizumab (300 mg monthly), because of its demonstrated efficacy in CSU¹ and low side-effect profile as compared to other agents used in treatment of alemtuzumab-related secondary autoimmunity. This resulted in a dramatic (but incomplete) reduction in urticaria, with burdensome breakthrough lesions typically in the week before her next omalizumab dose.

No clinical relapses or new signs of radiologic MS activity occurred over this period; her MS continued to improve throughout omalizumab therapy with the Expanded Disability Status Scale score improving from 2 to 0, over 18 months of monitoring.

A skin biopsy was performed that excluded other causes of immune-mediated urticaria, securing the diagnosis of CSU² (see figure 1 and figure e-1, links.lww.com/NXI/A186). Montelukast was initiated at 10 mg/d and advised to adhere to a strict 28-day dosing of omalizumab to minimize the breakthrough period.

From the Concord Repatriation General Hospital (H.H.); Brain and Mind Research Institute (S. Reddell), University of Sydney, Concord Repatriation General Hospital; and University of Sydney (S. Riminton, C.C., N.U.), Concord Repatriation General Hospital, Australia.

Go to Neurology.org/NN for full disclosures. Funding information is provided at the end of the article.

The Article Processing Charge was funded by the authors.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Figure A perilesional skin biopsy showed mild, superficial, dermal perivascular lymphocytic infiltrate and mild dermal oedema with dilated lymphatics

Neutrophils were seen within the lumen of the vessels and scattered in small numbers through interstitium together with occasional mast cells. The findings were consistent with chronic urticaria. No evidence of vasculitis was seen.

Discussion

Alemtuzumab is a monoclonal antibody directed against the CD52 antigen. It is used therapeutically in chronic lymphocytic leukemia and increasingly in MS. The CD52 antigen is expressed on >95% of peripheral B and T lymphocytes, monocytes, macrophages, and thymocytes. Binding of alemtuzumab to the CD52 antigen causes lysis of the target cell, and its clinical efficacy is because of B and T lymphocyte, monocyte, and natural killer cell depletion.³

Immune dysregulation after alemtuzumab has been reported at rates up to 30%, with common manifestations being thyroid diseases and autoimmune hematologic conditions.³ Autoimmune side effects manifested at 6 months with a peak incidence in year 3 after the first course.⁴ It is postulated the autoimmune sequelae arise from reconstitution of cells after T-cell lymphopenia along with additional insults including the depletion of Tregs and overproduction of interleukin-21.⁵ T cells undergo homeostatic proliferation to reconstitute the immune system relying on stimulation through the T-cell receptor-self peptide-major histocompatibility complex and leads to generation of self-reactive T cells.⁵

CSU is the appearance of wheals and/or angioedema for longer than 6 weeks.¹ It can be because of autoantibodies or idiopathy.² The treatment paradigm is high-dose H1-antagonists (up to 4 times the usual recommended dose), H2 antagonists, and adjuvants such as leukotriene antagonists. If symptoms remain refractory, the most effective next-line agent is omalizumab.

Omalizumab is a humanized immunoglobulin G directed against immunoglobulin E and is thought to not only bind serum IgE but also downregulate its cognate receptor (Fc ϵ R-1) on mast cells; it has demonstrated efficacy in severe, autoimmune CSU.⁶

We believe that this is the first reported case of CSU in the context of immune dysregulation within the typical time period after alemtuzumab and thus adds to the expanding repertoire of alemtuzumab-related immune-mediated side effects. Previous reports of urticaria were solely acute infusion-related side effects.⁷ It is important to consider CSU as a cause of recurrent rashes and angioedema after alemtuzumab because disease specific therapy is effective and available.

Study funding

No targeted funding reported.

Disclosure

Disclosures available: [Neurology.org/NN](https://www.neurology.org/NN).

Publication history

Received by *Neurology: Neuroimmunology & Neuroinflammation* May 24, 2019. Accepted in final form December 11, 2019.

Appendix Authors

Name	Location	Role	Contribution
Hannah Hu, MBBS, MMed	Concord Repatriation General Hospital, Australia	Author	Compilation of patient history; drafted the manuscript for intellectual content
Stephen Reddell, MBBS, PhD	Concord Repatriation General Hospital, University of Sydney, Australia	Author	Compilation of patient history; revised the manuscript for intellectual content
Sean Riminton, MBChB, PhD	Concord Repatriation General Hospital, University of Sydney, Australia	Author	Compilation of patient history; revised the manuscript for intellectual content
Charles Chan, MBBS, PhD	Concord Repatriation General Hospital, University of Sydney, Australia	Author	Compilation of patient history; interpreted the data
Nicolás Urriola, MBBS	Concord Repatriation General Hospital, University of Sydney, Australia	Author	Compilation of patient history; revised the manuscript for intellectual content

References

- Maurer M, Rosen K, Hsieh HJ, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. *N Engl J Med* 2013;368:924–935.
- Saini SS. Chronic spontaneous urticaria. *Immunol Allergy Clin North Am* 2014;34:33–52.
- Guarnera C, Bramanti P, Mazzon E. Alemtuzumab: a review of efficacy and risks in the treatment of relapsing remitting multiple sclerosis. *Ther Clin Risk Manag* 2017;13:871–879.
- Decallonne B, Bartholomé E, Delvaux V, et al. Thyroid disorders in alemtuzumab-treated multiple sclerosis patients: a Belgian consensus on diagnosis and management. *Acta Neurol Belg* 2018;118:153–159.
- Jones JL, Phuach CL, Cox AL, et al. IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H). *J Clin Invest* 2009;119:2052–2061.
- Kaplan AP. Chronic spontaneous urticaria: pathogenesis and treatment considerations. *Allergy Asthma Immunol Res* 2017;9:477–482.
- Uppenkamp M, Engert A, Diehl V, Bunjes D, Huhn D, Brittinger G. Monoclonal antibody therapy with CAMPATH-1H in patients with relapsed high- and low-grade non-Hodgkin's lymphomas: a multicenter phase I/II study. *Ann Hematol* 2002;81:26–32.

Neurology® Neuroimmunology & Neuroinflammation

Refractory chronic spontaneous urticaria after the use of alemtuzumab in multiple sclerosis

Hannah Hu, Stephen Reddell, Sean Riminton, et al.
Neurol Neuroimmunol Neuroinflamm 2020;7;
DOI 10.1212/NXI.0000000000000661

This information is current as of January 8, 2020

Neurol Neuroimmunol Neuroinflamm is an official journal of the American Academy of Neurology. Published since April 2014, it is an open-access, online-only, continuous publication journal. Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.. All rights reserved. Online ISSN: 2332-7812.

Updated Information & Services

including high resolution figures, can be found at:
<http://nn.neurology.org/content/7/2/e661.full.html>

References

This article cites 7 articles, 0 of which you can access for free at:
<http://nn.neurology.org/content/7/2/e661.full.html##ref-list-1>

Citations

This article has been cited by 1 HighWire-hosted articles:
<http://nn.neurology.org/content/7/2/e661.full.html##otherarticles>

Subspecialty Collections

This article, along with others on similar topics, appears in the following collection(s):

All Clinical Neurology

http://nn.neurology.org/cgi/collection/all_clinical_neurology

All Immunology

http://nn.neurology.org/cgi/collection/all_immunology

Autoimmune diseases

http://nn.neurology.org/cgi/collection/autoimmune_diseases

Multiple sclerosis

http://nn.neurology.org/cgi/collection/multiple_sclerosis

Permissions & Licensing

Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:

<http://nn.neurology.org/misc/about.xhtml#permissions>

Reprints

Information about ordering reprints can be found online:
<http://nn.neurology.org/misc/addir.xhtml#reprintsus>

Neurol Neuroimmunol Neuroinflamm is an official journal of the American Academy of Neurology. Published since April 2014, it is an open-access, online-only, continuous publication journal. Copyright Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.. All rights reserved. Online ISSN: 2332-7812.